Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Meguru Achira"'
Publikováno v:
Journal of Diabetes Investigation, Vol 11, Iss 2, Pp 373-381 (2020)
Abstract Introduction To investigate the efficacy and safety of trelagliptin 25 mg in patients with type 2 diabetes mellitus with severe renal impairment or end‐stage renal disease. Materials and Methods This multicenter, randomized, phase 3 study
Externí odkaz:
https://doaj.org/article/938dabafc6de4fc0bd13629af2ba05e3
Publikováno v:
Journal of Diabetes Investigation, Vol 11, Iss 2, Pp 373-381 (2020)
Journal of Diabetes Investigation
Journal of Diabetes Investigation
Introduction To investigate the efficacy and safety of trelagliptin 25 mg in patients with type 2 diabetes mellitus with severe renal impairment or end‐stage renal disease. Materials and Methods This multicenter, randomized, phase 3 study comprised
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8265854650d7627e4d90f5b94d67c82c
https://doaj.org/article/938dabafc6de4fc0bd13629af2ba05e3
https://doaj.org/article/938dabafc6de4fc0bd13629af2ba05e3
Autor:
Osamu Matsuoka, Meguru Achira, Masanori Watanabe, Tomoya Kagawa, Yusuke Moritoh, Harunobu Nishizaki
Publikováno v:
Diabetes. 70
The clinical potential of SCO-267, an orally available allosteric full agonist against GPR40 that regulates islet and gut hormone secretion, is largely unknown. Here, we present the first clinical study using the GPR40 full agonist. A randomized, sin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1a7904203449577b3f6385abd1ea0896
https://doi.org/10.2337/db21-751-p
https://doi.org/10.2337/db21-751-p
Autor:
Hiroshi Aikata, Kazushi Numata, Shunsuke Kondo, Junji Furuse, Meguru Achira, Masatoshi Kudo, Naoya Kato, Yoshitaka Inaba, Atsushi Hagihara, Shingo Kuroda, Masafumi Ikeda, Kenta Motomura, Akiko Kimura, Kaoru Tsuchiya, Manabu Morimoto
Publikováno v:
Journal of Gastroenterology
Background To evaluate the efficacy and safety of cabozantinib in Japanese patients with advanced hepatocellular carcinoma (HCC) who had progressed following one or two lines of systemic therapy including sorafenib. An exploratory evaluation in soraf
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35f0b913149816dacab326ec307e84a5
https://pubmed.ncbi.nlm.nih.gov/33392749
https://pubmed.ncbi.nlm.nih.gov/33392749
Publikováno v:
Current clinical pharmacology. 14(3)
Background: Exposure, safety and/or efficacy of drugs are subject to potential differences between human races or ethnicities, as acknowledged by regulatory guidance and by label texts of various, but not all approved drugs. Objective: The objective
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab7d53f7cfbc55322b62c14f1ba26b8b
https://pubmed.ncbi.nlm.nih.gov/30961506
https://pubmed.ncbi.nlm.nih.gov/30961506
Autor:
Michinori Ogura, Masafumi Taniwaki, Kiyoshi Ando, Junya Kuroda, Tatsuya Suzuki, Yu Abe, Dai Maruyama, Kensei Tobinai, Koho Iizuka, Kenshi Suzuki, Meguru Achira, Minoru Kojima
Publikováno v:
International Journal of Hematology. 101:286-294
Siltuximab, a chimeric monoclonal antibody with high affinity and specificity for interleukin-6, has been shown to enhance anti-multiple myeloma activity of bortezomib and corticosteroid in vitro. We evaluated the safety, pharmacokinetics, immunogeni
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea6649c90616e57aa7c353d382ec9931
https://doi.org/10.1007/s12185-015-1743-y
https://doi.org/10.1007/s12185-015-1743-y
Autor:
Kaoru Takanaka, Yukiharu Nakayama, Keiichi Ida, Shunichi Kametani, Toshio Inoda, Takashi Izumi, Masato Tani, Kouichi Nakamura, Eiji Kashiyama, Shigemichi Morita, Fukuichi Ohsawa, Shuichi Sakai, Meguru Achira, Akira Kagayama, Satoru Asahi, Nobuo Osawa, Jun Morita, Yoshinobu Yoshimura, Kimitoshi Saito, Yoshiaki Terauchi, Takuro Niwa, Osamu Takenaka, Takanori Hashizume, Kiyoshi Noguchi, Toshifumi Shiraga, Yasuhiro Nakai, Satoshi Omori, Akinori Aoyama, Takashi Kuwabara, Hiroyuki Kawai, Akio Nakamura, Toshiyuki Kume, Sekio Nagayama, Masahiko Iwasaki, Takuya Yoshimura, Mitsuaki Takeuchi, Hideki Nakamura, Takashi Kawashiro, Takeshi Nakabayashi
Publikováno v:
Drug Metabolism and Pharmacokinetics. 19:444-452
As a part of the studies conducted by the Pharma SNPs Consortium (PSC), the enzyme activities of CYP1A2, CYP2A6 and CYP2B6 variants with altered amino acids as a result of single nucleotide polymorphisms (SNPs) found among the Japanese population wer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf8022493d1f872622e180d5d0b15d9e
https://doi.org/10.2133/dmpk.19.444
https://doi.org/10.2133/dmpk.19.444
Comparative studies to determine the selective inhibitors for P-glycoprotein and cytochrome P 4503A4
Publikováno v:
AAPS PharmSci. 1:14-19
It has been suggested that cytochrome P450 3A4 (CYP3A4) and MDR1 P-glycoprotein (P-gp) act synergistically to limit the bioavailability of orally administered agents. In order to determine the relative role of these proteins, it is essential to ident
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::871091db418ec60b7b3b5fe5b25d8c53
https://doi.org/10.1208/ps010418
https://doi.org/10.1208/ps010418
Autor:
Joyce Ford, Zhenhua Xu, Jie Ling, Esther Bouman-Thio, Sally Lyn, Hugh M. Davis, Carrie Wagner, Kenneth Kim, Honghui Zhou, Gopi Shankar, Akira Shishido, Meguru Achira
Publikováno v:
Journal of clinical pharmacology. 50(7)
This phase 1 study evaluated the single-dose pharmacokinetics and safety of subcutaneous golimumab, a human anti-tumor necrosis factor-alpha monoclonal antibody, in healthy Japanese and Caucasian subjects. Eligible subjects were males, aged 20 to 45
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74af4ece9b6662d5b3ccedcd371b2fb1
https://pubmed.ncbi.nlm.nih.gov/20133508
https://pubmed.ncbi.nlm.nih.gov/20133508
Publikováno v:
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 16(1-2)
Cyclosporine A and steroids are effective against rheumatoid arthritis and also known as substrates of P-glycoprotein (P-gp). We investigated the effect of arthritis on the hepatic and intestinal P-gp activity in rats, and substantiated the expressio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85d990b73dbb0747a8af3c3463d8a1f4
https://pubmed.ncbi.nlm.nih.gov/12113888
https://pubmed.ncbi.nlm.nih.gov/12113888